RCS - Angle PLC - 100th publication supporting Parsortix system use

AngleAnnouncement

26/09/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240926:nRSZ7117Fa&default-theme=true

RNS Number : 7117F  Angle PLC  26 September 2024

 For immediate release  26 September 2024

 

ANGLE plc ("the Company")

 

100(TH) PUBLICATION SUPPORTING PARSORTIX SYSTEM USE

 

Whole Genomic Sequencing and machine learning identifies key cancer genes
associated with DNA proliferation and repair

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology, is pleased to announce the publication of
the 100(th) peer-reviewed journal article using the Parsortix(®) system for
the isolation, harvest and analysis of CTCs.

 

The journal article is published by researchers from a leading international
referral centre for the treatment and study of cancer, the Fondazione
IRCCS - Istituto Nazionale dei Tumori Di Milano (Italy). It reports on the
isolation of CTCs from triple negative breast cancer patients for analysis
using single cell isolation and whole genomic sequencing (WGS). WGS is the
most comprehensive genetic test available, sequencing an individual's entire
genome to reveal unique mutations that may be present in cancer cells.
Although not yet routinely used in clinical practice, WGS can allow the
identification of genetic drivers of cancer and potential new targeted
treatments. In this study the Parsortix system harvested intact cancer cells
from patient blood samples for WGS. Sequencing data was analysed using a
machine learning algorithm to identify cancer genes associated with DNA
proliferation and repair. The authors conclude that this cost-effective
sequencing assay has the potential to guide clinical patient management.

 

The 100 publications using the Parsortix system span a decade of research
across 24 cancer types responsible for 90% of cases of solid cancers. Research
has been borne out of 42 independent research institutes, hospitals and
universities in 15 countries covering Europe, UK, US, and Australia. During
this time CTC analysis has evolved from simple enumeration to predict patient
prognosis, to the detailed analysis of clinically relevant biomarkers using
immunofluorescence, PCR and next generation sequencing (NGS). These downstream
molecular analyses have evolved to provide highly accurate, fast and
cost-effective testing with the potential to rapidly advance the personalised
treatment of cancer.

 

Chief Scientific Officer, Karen Miller, commented:

"This publication marks a decade of independent research where the Parsortix
system has been used to provide insights into tumour biology, metastatic
progression and treatment response.

 

Whilst ctDNA profiling is more established in the clinic, in recent years
there has been an increase in the number of publications analysing both CTCs
and ctDNA. These studies have found that CTCs can provide additional and
complementary information to ctDNA or tissue alone and therefore a more
comprehensive view of the tumour and its interaction with the
microenvironment. We firmly believe that multi-analyte assessment holds the
potential to unlock the full clinical capabilities of liquid biopsy as a less
invasive and more cost-effective alternative to tissue biopsy."

 

The research has been published as a peer-reviewed publication in the journal
Scientific Reports is available online at
https://angleplc.com/resources/publications/.

 

For further information:

 

 ANGLE plc                               +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Broker)            +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 FTI Consulting

 Simon Conway, Ciara Martin              +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                +1 (212) 850 5624

 

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and patent protected
CTC harvesting technology known as the Parsortix(®) PC1 System enables
complete downstream analysis of the sample including whole cell imaging and
proteomic analysis and full genomic and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on diagnostic products and clinical
services. Products include the Parsortix system, associated consumables and
assays. The clinical services business is offered through ANGLE's
GCLP-compliant laboratories. Services include custom made assay development
and clinical trial testing for pharma.

 

100 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

 

 

Any reference to regulatory authorisations such as FDA clearance, CE marking
or UK MHRA registration shall be read in conjunction with the full intended
use of the product:

 

The Parsortix(®) PC1 system is an in vitro diagnostic device intended to
enrich circulating tumor cells (CTCs) from peripheral blood collected in
K(2)EDTA tubes from patients diagnosed with metastatic breast cancer.  The
system employs a microfluidic chamber (a Parsortix cell separation cassette)
to capture cells of a certain size and deformability from the population of
cells present in blood. The cells retained in the cassette are harvested by
the Parsortix PC1 system for use in subsequent downstream assays. The end user
is responsible for the validation of any downstream assay. The standalone
device, as indicated, does not identify, enumerate or characterize CTCs and
cannot be used to make any diagnostic/prognostic claims for CTCs, including
monitoring indications or as an aid in any disease management and/or treatment
decisions.

 

All results reported in this announcement and any other products and services
are for research use only and not for use in diagnostic procedures.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPPUAPBUPCPGA